BMTCN indications for treatment 2023/2024 passed

Malignant diseases - correct answer Leukemias, lymphomas, dysplastic syndromes, proliferative syndrome Non-malignant diseases - correct answer Hemoglobinopathies, inadequate hematopoiesis, metabolic disorders, immune deficits Acute Lymphoblastic Leukemia - correct answer 1st = Allogeneic stem cell transplant; 2nd= Allogeneic transplant Acute myeloid leukemia - correct answer 1st = Allogeneic 2nd = Allogeneic Myelodysplastic syndrome - correct answer Allogeneic Acute promyelocytic lukemia - correct answer SCT not recommended Chronic lymphocytic lukemia - correct answer Allogeneic Chronic myeloid lukemia - correct answer Allogeneic Hodgkin's lymphoma - correct answer Auto = relapsed after primary chemotherapy; Allo = chemo-sensitive patients refractory or relapsed HL; syngeneic; BMT is not first line therapy Aggressive histology NHL: Diffuse B Cell Lymphoma and Aggressive T cell lymphomas - correct answer auto = recommended after relapse; allo = if not auto; not a part of primary therapy Follicular Lymphoma - correct answer auto & allo selected for patients with poor prognosis, third line Multiple myeloma - correct answer auto = recommended for young patients newly diagnosed; Tandem autologous = obtain less than complete response to first auto transplant; repeat auto = relapse after long remission (>2 yrs) to a single auto SCT; allo = high-risk cytogenetics and unresponsive to primary therapy Burkitt's lymphoma - correct answer auto and allo options beyond first remission Mantle cell lymphoma - correct answer auto = in first remission; auto or allo - 2nd remission Solid tumors - correct answer auto = gonadal or retroperitoneal germ cell tumors refractory or relapsed; not recommended in other solid tumors Aplastic anemia - correct answer allo ; auto not recommended